Acute Exacerbation of Chronic Obstructive Pulmonary Disease Patient Registry in China (AECOPD-PRC): Study Protocol
Ting Yang,Zhengcun Pei,Sinan Wu,Shengfeng Wang,Kewu Huang,Yahong Chen,Xiaolei Zhang,Yan Zhang,Chen Wang,Siyan Zhan
DOI: https://doi.org/10.1016/j.chest.2016.02.380
IF: 9.6
2016-01-01
Chest
Abstract:SESSION TITLE: COPD Exacerbations SESSION TYPE: Original Investigation Poster PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM PURPOSE: To investigate the demographic characteristics, clinical features, diagnoses and treatments of AECOPD hospitalized patients, and disease prognosis and its economic burden. METHODS: AECOPD-PRC plans to enroll 8100 hospitalized patients (≥ 18 years old with main diagnosis as AECOPD). Sample size estimation is based on estimated mortality of AECOPD hospitalized patients (∼5%). Study patients will be recruited from 108 hospitals across China, hospital selection follows the principle of stratification sampling (by provinces, municipalities, and special administration regions). Study patients will be recruited from Oct 2015, followed with a 3-year period visit. Ten visits are scheduled for each patient, including Visit 1 (within 3d after hospitalized), Visit 2 (the day discharged from hospital), Visit 3 to Visit 10 (1mo, 3mo, 6mo, 12mo, 18mo, 24mo, 30mo, 36mo after discharged, respectively). Over the period of hospital stay, information on demographic characteristics, clinical features, diagnoses (lung function, laboratory and imaging examinations, etc) and treatments will be collected. In the following visits, treatments and examinations, recurrence of AECOPD, re-admission to hospital, complications and mortality will be recorded. Additionally, several validated questionnaires will be applied at specific visits, including CAT, SGRQ and HADS. The primary study outcomes are all-cause mortality during hospital stay, AECOPD recurrence within 1mo after discharged. Secondary outcomes include all-cause and cause-specific mortality, frequency of AECOPD recurrence, lung function, life quality, health care costs in the 3-year study period, etc. RESULTS: N.A. CONCLUSIONS: As the first step for proper measuring mortality of AECOPD patients all over the country, this study will enable our clinicians and researchers to address foundational issues regarding the current status of AECOPD in China. It will also serve as a harmonized, evidence-based registry and platform for conducting future research, which will ultimately improve the management care provided to AECOPD patients. CLINICAL IMPLICATIONS: This study will describe the overall clinical features and treatment procedures of AECOPD patients, contribute to the current knowledge of clinical experience, and ultimately improve clinical practice. DISCLOSURE: The following authors have nothing to disclose: Ting Yang, Zhengcun Pei, Sinan Wu, Shengfeng Wang, Kewu Huang, Yahong Chen, Xiaolei Zhang, Yan Zhang, Chen Wang, Siyan Zhan No Product/Research Disclosure Information